NCT05322499

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Second-line or Above Therapy for Advanced Esophageal Squamous Cell Cancer Previously Treated With First-line Immunotherapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To observe and evaluate the efficacy and safety of camrelizumab combined with chemotherapy or anlotinib in patients with advanced esophageal squamous cell carcinoma previously Treated With First-line Immunotherapy

Detailed description

How to improve the efficacy of immunotherapy, evaluate the results of immunotherapy more objectively, and overcome immune resistance through reasonable combined treatment methods, so as to maximize the benefit of patients from immunotherapy, is an urgent research direction to be explored. Therefore, this study intends to observe and evaluate the efficacy and safety of camrelizumab combined with chemotherapy or anlotinib in patients with advanced esophageal squamous cell cancer previously Treated With First-line Immunotherapy . It can provide a basis for the treatment of esophageal cancer after immune resistance.

Conditions

• Stage IV Esophagus Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Camrelizumab	200mg/dose intravenous infusion, D1, once every 3 weeks (q3w);
DRUG	Irinotecan	100-125mg/m2，d1，d8；q21d
DRUG	Paclitaxel	135-175mg/m2，d1，Q3W
DRUG	Paclitaxel-albumin	100-135mg/m2, d1、d8，Q3W
DRUG	Docetaxel	60-75mg/m2，d1，Q3W
DRUG	Anlotinib	12mg，qd，d1-d14，q3w

Timeline

• Start date: 2022-04-15
• Primary completion: 2023-04-15
• Completion: 2025-04-15
• First posted: 2022-04-11
• Last updated: 2022-04-11

Locations

1 site across 1 country: China